Federal Register #2026-16444

Exclusive Patent Licensing for BL-760 Dye, Anti-CE1 Antibodies, and CRISPR-Engineered Cancer Cell Line

This opportunity from the National Cancer Institute (NCI), part of the National Institutes of Health, offers exclusive patent licensing for innovative cancer research tools and therapeutics. - Government Buyer: - National Institutes of Health (NIH) - National Cancer Institute (NCI) - Technology Transfer Center - OEMs and Vendors: - OptoSurgical LLC (prospective licensee for BL-760 dye) - Products/Technologies Available for Licensing: - BL-760 Dye - Stable heptamethine cyanine fluorophores for intraoperative fluorescence imaging - Patent families: E27120140 and E04620190 - Application: Visualization of bile duct and biliary structures during hepatopancreato-biliary surgery - Human anti-CE1 B9 and B10 Antibodies - Part number: E0212025 - Therapeutic antibodies targeting hepatocellular carcinoma (liver cancer) - Pre-clinical stage, potential for immunoconjugate development - MC38 B2m Knockout Murine Colon Cancer Cell Line - Part number: E12320260 - CRISPR/Cas9-engineered cell line modeling resistance to PD-1/PD-L1 checkpoint blockade - Used for immuno-oncology research and evaluation of alternative immunotherapies - Notable Requirements: - Exclusive, royalty-bearing patent license for BL-760 dye - Field of use limited to development, manufacture, and commercialization for intraoperative imaging of biliary structures in humans - Opportunity is open for written comments or competing license applications - Intellectual property is assigned to the US Government

Description

The National Cancer Institute, part of the National Institutes of Health under the Department of Health and Human Services, is considering granting an exclusive patent license to OptoSurgical LLC for inventions related to BL-760 dye. This dye is intended for intraoperative fluorescence imaging to visualize the bile duct and small biliary structures during hepatopancreato-biliary surgery in humans. The license covers patents and patent applications related to stable heptamethine cyanine fluorophores and their biomedical applications. Interested parties may submit written comments or license applications by August 27, 2026.

View original listing